ABEO
Abeona Therapeutics Inc.
There isn't enough reported data to score ABEO yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ABEO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Under pressure | |
| Unavailable |
ABEO's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ABEO PE Valuation
ABEO has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ABEO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ABEO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ABEO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.09 | -192% |
| Q2 2026 | -$1.11 | -271% |
| Q1 2026 | $0.95 | +$2.27 |
| Q4 2025 | $1.01 | +$3.25 |
| Q3 2025 | $1.18 | +$3.82 |
| Q2 2025 | $0.65 | +$3.14 |
| Q1 2025 | -$1.32 | +$1.83 |
| Q4 2024 | -$2.24 | +$0.29 |
ABEO has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ABEO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.4M | +2745% |
| Q2 2023 | $3.5M | +250% |
ABEO's revenue has grown year over year for four quarters in a row: $13M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -96% | N/A |
| Q2 2026 | -120% | +5578 points |
| Q1 2026 | -264% | N/A |
| Q4 2025 | -423% | N/A |
| Q2 2025 | -5698% | N/A |
| Q2 2023 | -302% | +499 points |
| Q4 2022 | -19024% | N/A |
| Q2 2022 | -801% | N/A |
ABEO's operating margin was −96% last quarter, up 5602 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ABEO on profitability, with a higher operating margin.
ABEO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.5M | +$15.2M |
| Q2 2026 | -$18M | +$3.7M |
| Q1 2026 | -$20.7M | -$936K |
| Q4 2025 | -$19.1M | -$1.9M |
| Q3 2025 | -$23.7M | -$11.1M |
| Q2 2025 | -$21.7M | -$8.3M |
| Q1 2025 | -$19.8M | -$4.5M |
| Q4 2024 | -$17.2M | -$7.9M |
ABEO has burned cash in almost every quarter: −$66M over the past year, against −$82M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ABEO on cash generation, producing positive trailing cash flow while its opponent burns cash.
ABEO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.4% | +810K shares |
| 1 year | +6.7% | +3.6M shares |
| 3 years | +221% | +39.8M shares |
| 5 years | +1461% | +54.2M shares |
| Available history | +2543% | +55.7M shares |
ABEO has 58M diluted shares, up 6.7% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ABEO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ABEO Net Leverage
ABEO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ABEO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.4 | Oversold |
| Stochastic | 3.4 | Oversold |
ABEO's weekly RSI is 23 (oversold) and its Stochastic is 3 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ABEO PE vs Healthcare Sector
| Metric | ABEO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ABEO has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ABEO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.38 | 48% below |
| 20 week MA | $5.50 | 58% below |
| 50 week MA | $5.34 | 57% below |
| 100 week MA | $5.51 | 58% below |
| 200 week MA | $5.09 | 55% below |
ABEO is in a downtrend: it's below all five of its weekly moving averages, and 55% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ABEO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.5 | $43.3 | -49% |
| 2021 | $43.3 | $9.00 | -79% |
| 2022 | $9.00 | $2.51 | -72% |
| 2023 | $2.51 | $5.01 | +100% |
| 2024 | $5.01 | $5.63 | +12% |
| 2025 | $5.63 | $5.45 | -3.2% |
| 2026 YTD | $5.45 | $2.29 | -58% |
ABEO has finished lower in four of the last six years. It's down 58% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ABEO on returns for 2026, with the stronger performance.